The Genetic and Clinical Significance of Fetal Hemoglobin Expression in Sickle Cell Disease

Abstract

Sickle cell disease (SCD) is phenotypically heterogeneous. One major genetic modifying factor is the patient’s fetal hemoglobin (HbF) level. The latter is determined by the patient’s β-globin gene cluster haplotype and <i>cis</i>- and <i>trans</i>-acting single nucleotide polymorphisms (SNPs) at other distant quantitative trait loci (QTL). The Arab/India haplotype is associated with persistently high HbF levels and also a relatively mild phenotype. This haplotype carries the <i>Xmn1</i> (C/T) SNP, rs7482144, in the <i>HBG2</i> locus. The major identified trans-acting QTL contain SNPs residing in the <i>BCL11A</i> on chromosome 2 and the <i>HMIP</i> locus on chromosome 6. These collectively account for 15–30% of HbF expression in different world populations and in patients with SCD or β-thalassemia. Patients with SCD in Kuwait and Eastern Saudi Arabia uniformly carry the Arab/India haplotype, but despite this, the HbF and clinical phenotypes show considerable heterogeneity. Pain episodes and avascular necrosis of the femoral head are particularly common, but severe bacterial infections, stroke, priapism, and leg ulcers are uncommon. Moreover, the HbF modifiers appear to be different; the reported <i>BCL11A</i> and <i>HMIP</i> SNPs appear to play insignificant roles. There are probably novel modifiers to be discovered in this population. This review examines the common clinical phenotypes in Kuwaiti patients with elevated HbF and the available information on HbF modifiers. The response of the patients to hydroxyurea is discussed. The presentation of patients with other sickle compound heterozygotes (Sβthal and HbSD), vis-à-vis their HbF levels, is also addressed critically.